Company
Pyxis Oncology
Nasdaq: PYXS
Boston, Massachusetts biopharmaceutical company, Nasdaq-listed since its 2021 IPO. Developing MICVO (micvotabart pelidotin), an antibody-drug conjugate targeting a structural protein in the tumor microenvironment, for recurrent or metastatic head and neck cancer.
1 story
Regulatory News has published 1 story about Pyxis Oncology on 4 October 2026, sourced to the primary record — the regulator’s decision, the company’s filing or its own announcement. This page is generated from that coverage. Last updated 4 October 2026.
This page is generated from Regulatory News’ editorial coverage of Pyxis Oncology. It is not an advertisement.
On the record
- Company
- Pyxis Oncology, Inc. (Nasdaq: PYXS)
- Headquarters
- Boston, Massachusetts
- Founded
- Publicly launched July 2019, by the Longwood Fund with Thomas Gajewski, M.D., Ph.D. and John Flavin
- Regulator
- U.S. Securities and Exchange Commission (MICVO separately holds FDA Fast Track Designation)
Each line is taken from the most recent story of ours that states it.
Products in our coverage
Our coverage
